NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has included two molecular diagnostics – Myriad Genetics' Prolaris and Genomic Health's Oncotype DX Prostate Cancer – in its most recent guidelines for the disease, noting that these two assays "appear further along in development a
NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has approved inclusion of Biodesix's VeriStrat proteomics test in its guidelines for non-small cell lung cancer, the Boulder, Colo.-based firm said today.
The National Comprehensive Cancer Network now supports MGMT methylation testing in elderly glioblastoma patients to assess the likelihood that they will benefit from temozolomide treatment. This may help spur adoption of MDxHealth's MGMT PredictMDx for Glioblastoma test.
